<< Back to News

System Formulary Update
Teplizumab (Tzield)

Situation:

Teplizumab (Tzield) 2 mg/2 mL SDV intravenous solution for injection was approved for addition to the UNC Health System Formulary at the April 2023 System Pharmacy and Therapeutics Committee meeting.

Background:

The following medications were reviewed: Teplizumab (Tzield) 2 mg/2 mL SDV intravenous solution for injection 

Assessment/Recommendations:

System P&T voted to include the following product from the UNC Health Medication Formulary:

• Teplizumab (Tzield) 2 mg/2 mL SDV intravenous solution for injection

Note: Stock of this formulary product may vary at individual entities 

Formulary/Epic Changes will Go-Live on Tuesday, April 30, 2024